Alaunos Therapeutics
TCRT
140 hedge funds and large institutions have $306M invested in Alaunos Therapeutics in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 26 closing their positions.
112% more call options, than puts
Call options by funds: $29.1M | Put options by funds: $13.7M
2% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $328M → $306M (-$22.2M)
9% less funds holding
Funds holding: 154 → 140 (-14)
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
+$2.18M |
| 2 |
Renaissance Technologies
New York
|
+$1.69M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$1.65M |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$1.5M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.53M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$3.28M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$2.89M |
TCRT Hedge Fund Activity: Q3 2016 in Review
140 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2016, worth a combined $306M — down 6.8% from $328M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of TCRT and 13 opened new positions — a net loss of 13 holders — while 41 trimmed existing stakes and 42 added.
The largest buyer was Belmont Global Advisors, adding an estimated $2.18M. The largest seller was Fidelity Investments, exiting entirely with an estimated $10.7M sold.
- 140 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2016, down from 154 in Q2 2016.
- Funds reported $306M of Alaunos Therapeutics stock for Q3 2016, down 6.8% quarter-over-quarter.
- 13 funds opened new Alaunos Therapeutics positions in Q3 2016 and 26 closed out, a net change of -13 holders.
- The largest Alaunos Therapeutics buyer in Q3 2016 was Belmont Global Advisors, an estimated $2.18M added.
- The largest Alaunos Therapeutics seller in Q3 2016 was Fidelity Investments, an estimated $10.7M sold.
Based on aggregated 13F filings for Q3 2016.